vs
Citizens Financial Group（CFG）与晖致（VTRS）财务数据对比。点击上方公司名可切换其他公司
晖致的季度营收约是Citizens Financial Group的1.7倍（$3.7B vs $2.2B），Citizens Financial Group同比增速更快（8.6% vs 5.0%），过去两年Citizens Financial Group的营收复合增速更高（4.9% vs 0.5%）
Citizens Financial Group, Inc.是美国银行控股企业，总部位于罗德岛州普罗维登斯，旗下拥有Citizens Bank国民银行，业务覆盖康涅狄格、特拉华、佛罗里达、纽约等十余个美国州份及华盛顿特区，为当地客户提供各类银行金融服务。
晖致是一家总部位于美国宾夕法尼亚州卡农斯堡的全球化医药健康企业，于2020年11月16日由迈兰制药与辉瑞旗下老牌业务部门普强合并组建，业务覆盖全球多个国家和地区，专注为大众提供优质的医药健康产品及服务。
CFG vs VTRS — 直观对比
营收规模更大
VTRS
是对方的1.7倍
$2.2B
营收增速更快
CFG
高出3.6%
5.0%
两年增速更快
CFG
近两年复合增速
0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.2B | $3.7B |
| 净利润 | $528.0M | — |
| 毛利率 | — | 31.1% |
| 营业利润率 | 31.4% | -5.2% |
| 净利率 | 24.5% | — |
| 营收同比 | 8.6% | 5.0% |
| 净利润同比 | 31.7% | — |
| 每股收益（稀释后） | $1.12 | $-0.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CFGVTRS
| Q4 25 | $2.2B | $3.7B | ||
| Q3 25 | $2.1B | $3.7B | ||
| Q2 25 | $2.0B | $3.6B | ||
| Q1 25 | $1.9B | $3.2B | ||
| Q4 24 | $2.0B | $3.5B | ||
| Q3 24 | $1.9B | $3.7B | ||
| Q2 24 | $2.0B | $3.8B | ||
| Q1 24 | $2.0B | $3.7B |
净利润CFGVTRS
| Q4 25 | $528.0M | — | ||
| Q3 25 | $494.0M | — | ||
| Q2 25 | $436.0M | — | ||
| Q1 25 | $373.0M | — | ||
| Q4 24 | $401.0M | — | ||
| Q3 24 | $382.0M | — | ||
| Q2 24 | $392.0M | — | ||
| Q1 24 | $334.0M | — |
毛利率CFGVTRS
| Q4 25 | — | 31.1% | ||
| Q3 25 | — | 36.6% | ||
| Q2 25 | — | 37.3% | ||
| Q1 25 | — | 35.8% | ||
| Q4 24 | — | 34.6% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | — | 38.2% | ||
| Q1 24 | — | 41.2% |
营业利润率CFGVTRS
| Q4 25 | 31.4% | -5.2% | ||
| Q3 25 | 29.7% | 4.8% | ||
| Q2 25 | 27.2% | 6.5% | ||
| Q1 25 | 24.2% | -88.9% | ||
| Q4 24 | 25.6% | -5.1% | ||
| Q3 24 | 24.7% | 6.0% | ||
| Q2 24 | 24.5% | -6.3% | ||
| Q1 24 | 21.9% | 5.6% |
净利率CFGVTRS
| Q4 25 | 24.5% | — | ||
| Q3 25 | 23.3% | — | ||
| Q2 25 | 21.4% | — | ||
| Q1 25 | 19.3% | — | ||
| Q4 24 | 20.2% | — | ||
| Q3 24 | 20.1% | — | ||
| Q2 24 | 20.0% | — | ||
| Q1 24 | 17.0% | — |
每股收益（稀释后）CFGVTRS
| Q4 25 | $1.12 | $-0.34 | ||
| Q3 25 | $1.05 | $-0.11 | ||
| Q2 25 | $0.92 | $0.00 | ||
| Q1 25 | $0.77 | $-2.55 | ||
| Q4 24 | $0.83 | $-0.43 | ||
| Q3 24 | $0.77 | $0.08 | ||
| Q2 24 | $0.78 | $-0.27 | ||
| Q1 24 | $0.65 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.3B |
| 总债务越低越好 | $11.2B | — |
| 股东权益账面价值 | $26.3B | $14.7B |
| 总资产 | $226.4B | $37.2B |
| 负债/权益比越低杠杆越低 | 0.43× | — |
8季度趋势，按日历期对齐
现金及短期投资CFGVTRS
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $975.3M | ||
| Q2 25 | — | $566.4M | ||
| Q1 25 | — | $755.0M | ||
| Q4 24 | — | $734.8M | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | — | $917.2M | ||
| Q1 24 | — | $1.0B |
总债务CFGVTRS
| Q4 25 | $11.2B | — | ||
| Q3 25 | $10.4B | — | ||
| Q2 25 | $12.5B | — | ||
| Q1 25 | $12.3B | — | ||
| Q4 24 | $12.4B | — | ||
| Q3 24 | $13.9B | — | ||
| Q2 24 | $13.1B | — | ||
| Q1 24 | $13.8B | — |
股东权益CFGVTRS
| Q4 25 | $26.3B | $14.7B | ||
| Q3 25 | $25.8B | $15.2B | ||
| Q2 25 | $25.2B | $15.6B | ||
| Q1 25 | $24.9B | $15.7B | ||
| Q4 24 | $24.3B | $18.6B | ||
| Q3 24 | $24.9B | $19.8B | ||
| Q2 24 | $23.9B | $19.5B | ||
| Q1 24 | $23.8B | $20.0B |
总资产CFGVTRS
| Q4 25 | $226.4B | $37.2B | ||
| Q3 25 | $222.7B | $37.9B | ||
| Q2 25 | $218.3B | $38.4B | ||
| Q1 25 | $220.1B | $38.5B | ||
| Q4 24 | $217.5B | $41.5B | ||
| Q3 24 | $219.7B | $44.8B | ||
| Q2 24 | $219.9B | $45.3B | ||
| Q1 24 | $220.4B | $47.3B |
负债/权益比CFGVTRS
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.40× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.56× | — | ||
| Q2 24 | 0.55× | — | ||
| Q1 24 | 0.58× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.2B | $815.8M |
| 自由现金流经营现金流 - 资本支出 | — | $619.3M |
| 自由现金流率自由现金流/营收 | — | 16.8% |
| 资本支出强度资本支出/营收 | — | 5.3% |
| 现金转化率经营现金流/净利润 | 4.19× | — |
| 过去12个月自由现金流最近4个季度 | — | $1.9B |
8季度趋势，按日历期对齐
经营现金流CFGVTRS
| Q4 25 | $2.2B | $815.8M | ||
| Q3 25 | $1.7B | $744.9M | ||
| Q2 25 | $886.0M | $219.7M | ||
| Q1 25 | $-213.0M | $535.5M | ||
| Q4 24 | $2.0B | $482.7M | ||
| Q3 24 | $130.0M | $826.5M | ||
| Q2 24 | $834.0M | $379.1M | ||
| Q1 24 | $554.0M | $614.6M |
自由现金流CFGVTRS
| Q4 25 | — | $619.3M | ||
| Q3 25 | — | $658.1M | ||
| Q2 25 | — | $166.8M | ||
| Q1 25 | — | $492.9M | ||
| Q4 24 | — | $342.3M | ||
| Q3 24 | — | $749.5M | ||
| Q2 24 | — | $320.3M | ||
| Q1 24 | — | $564.8M |
自由现金流率CFGVTRS
| Q4 25 | — | 16.8% | ||
| Q3 25 | — | 17.6% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | — | 15.2% | ||
| Q4 24 | — | 9.7% | ||
| Q3 24 | — | 20.1% | ||
| Q2 24 | — | 8.5% | ||
| Q1 24 | — | 15.5% |
资本支出强度CFGVTRS
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | 1.6% | ||
| Q1 24 | — | 1.4% |
现金转化率CFGVTRS
| Q4 25 | 4.19× | — | ||
| Q3 25 | 3.43× | — | ||
| Q2 25 | 2.03× | — | ||
| Q1 25 | -0.57× | — | ||
| Q4 24 | 4.99× | — | ||
| Q3 24 | 0.34× | — | ||
| Q2 24 | 2.13× | — | ||
| Q1 24 | 1.66× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CFG
暂无分部数据
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
